Hugel Launches Letybo Botulinum Toxin
Hugel Inc., renowned for its contributions to global medical aesthetics, has made a significant move by launching its botulinum toxin product, Letybo, in Malaysia. This strategic introduction is aimed at strengthening brand experiences among local medical professionals through academic events and hands-on workshops.
Collaboration with Venusys Medical
The launch of Letybo is in collaboration with Venusys Medical, a key partner in Malaysia. This partnership not only solidifies Hugel's position in the premium toxin products market but also enhances educational opportunities for medical practitioners. At the recent Aesthetic Medicine & Surgery Conference & Exhibition (AMSC), the largest of its kind in Malaysia, attendees were introduced to Letybo, marking a pivotal moment for local aesthetics.
Educational Events and Workshops
A noteworthy event occurred where Konstantin Frank, a leading figure in Europe regarding Letybo, delivered a comprehensive presentation at AMSC. He stressed the importance of precise treatment outcomes from botulinum toxin procedures and provided clinical strategies to elevate procedural results. Following this, a hands-on workshop took place, focusing on advanced injection techniques that combine anatomical understanding with practical clinical expertise, attracting around 100 local professionals.
Future Training Initiatives
The commitment from Hugel to provide customized training continues as they aim to enhance the customer experience for their premium toxin brand. By working closely with Venusys Medical, Hugel is set to expand its market presence further in Malaysia, ensuring that local medical practitioners are well-equipped with the latest knowledge and skills.
About Hugel Inc.
Founded in 2001, Hugel has established itself as a global leader in medical aesthetics, focusing on a variety of injectables for skin rejuvenation, including botulinum toxin and hyaluronic acid fillers. Recognized as the market leader in injectable aesthetics within South Korea, Hugel holds the unique position of being the only Korean company with regulatory approvals to operate in the largest botulinum toxin markets worldwide, including the US, China, and Europe. With an unwavering commitment to safety and quality, Hugel actively promotes industry advancement through extensive training programs and medical affairs.
Over the last two decades, Hugel has expanded its reach to approximately 70 countries, with operational subsidiaries in the US, Australia, Canada, Taiwan, Mainland China, Hong Kong, Singapore, and Thailand. The company continues to show robust growth and remains well-equipped to navigate future market expansions.
Frequently Asked Questions
What is Letybo?
Letybo is a new botulinum toxin product launched by Hugel Inc. aimed at enhancing aesthetic medical procedures.
Who is partnering with Hugel for the launch of Letybo?
The launch is in collaboration with Venusys Medical, a distributor of aesthetic products in Malaysia.
What type of events is Hugel organizing for medical professionals?
Hugel is organizing workshops and training programs to enhance the skills of local medical professionals regarding botulinum toxin procedures.
Where was Letybo launched?
Letybo was officially launched at the Aesthetic Medicine & Surgery Conference & Exhibition in Malaysia.
How long has Hugel been in operation?
Hugel was established in 2001, marking over 20 years in the medical aesthetics sector.